TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #237183

Testing ordered > 22 SEP '26

Sample received > 06 OCT '26

Client SPEPS/group

Sample Tesamorelin 10mg

Manufacturer SPEPS/group

Batch Unknown

Sample description >

See picture or pictures attached.

Tests requested >

Tesamorelin analysis

Results >

Tesamorelin	11.06 mg
Purity	97.140%

Comments>

Analysis conducted > 07 OCT 2026

Signature>



TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #237185

Testing ordered > 22 SEP '26

Sample received > 06 OCT '26

Client SPEPS/group

Sample Tesamorelin 10mg

Manufacturer SPEPS/group

Batch

Sample description >

See picture or pictures attached.

Tests requested >

LCMS Screening For Peptide Contamination

Results >

LCMS screening	

Comments>

LCMS analysis identified the presence of mannitol and tesamorelin. LCMS spectra are attached. No significant contamination detected.

Analysis conducted > 08 OCT 2026

Signature>




SHIMADZU
LabSolutions

Analysis Report

<Sample Information>


Sample Name	: 31995-8 Tesamorelin 10mg+LCMS scr.+HM Sample ID 014		
Data Filename	: 31995-8 Tesamorelin 10mg+LCMS scr.+HM_014_LCMS screening_014.lcd		
Method Filename	: LCMS screening.lcm		
Batch Filename	: 20261006-8+shutdown.lcb		
Vial #	: 3-7	Sample Type	: Unknown
Injection Volume	: 0.1 uL		
Date Acquired	: 06/10/2026 17:17:22	Acquired by	: System
Administrator Date Processed	: 06/10/2026 17:25:53	Processed by	: System Administrator

<Chromatogram>




MS Spectrum

Peak#:1 R.Time:0.276(Scan#:111)
MassPeaks:693
Spectrum Mode:Averaged 0.203-0.405(82-163) BG Mode:Calc Segment 1 - Event 1



Peak#:2 R.Time:5.434(Scan#:2175)
MassPeaks:1388
Spectrum Mode:Averaged 5.348-5.768(2140-2308)
BG Mode:Calc Segment 1 - Event 1



LC-MS Screening Summary

Tesamorelin | Sample 31995-8

Client-facing analytical summary


Summary

LC-MS screening shows an early mannitol-related chromatographic peak at approximately RT 0.273 min and a principal peptide-related peak at RT 5.433 min. The peptide-region MS1 spectrum contains prominent ions near m/z 1285.95, 1028.40, 857.10, 734.75 and 643.00, forming a coherent 4+, 5+, 6+, 7+ and 8+ charge-state series compatible with Tesamorelin-related material. Identification is provisional at screening resolution; this analysis does not establish quantitative purity.

Parameter	Observation
Analysis	LC-MS screening, positive-ion MS1
Sample	31995-8 Tesamorelin, 10 mg
Mannitol-related region	Approx. RT 0.273 min
Main peptide-related region	Approx. RT 5.433 min
Representative spectrum	RT 5.433 min
Prominent ions	m/z 1285.95 (4+), 1028.40 (5+), 857.10 (6+), 734.75 (7+), 643.00 (8+)
Mass interpretation	Approximate neutral mass 5136 Da from charge-state series; screening-level estimate
Overall assessment	Tesamorelin-related material detected; provisional MS1 assignment

Chromatographic profile


Figure 1. MS1 total ion chromatogram (TIC), showing the early mannitol-related peak and the principal Tesamorelin-related peak.



Chromatographic comment. The early peak at approximately RT 0.273 min contains m/z 204.75 and 182.80, compatible at nominal mass resolution with mannitol-related ions. A separate dominant peptide-related peak is observed near RT 5.433 min. Smaller features occur elsewhere in the chromatogram; TIC peak intensities cannot be used directly to establish quantitative purity.

Mass spectrum of the principal region

Figure 2. Representative positive-ion MS1 spectrum at RT 5.433 min, showing the peptide-related charge-state series.



Interpretation

• Ions near m/z 1285.95, 1028.40, 857.10, 734.75 and 643.00 are consistent with approximate 4+, 5+, 6+, 7+ and 8+ charge states, respectively, corresponding to a neutral peptide mass near 5.14 kDa.

• This pattern is compatible with the expected mass region of Tesamorelin. At nominal MS1 resolution, exact intact mass, terminal modifications and peptide sequence are not established definitively; a higher-resolution/deconvoluted method would be required.

• The early peak at RT 0.273 min is consistent with mannitol-related material, including m/z 204.75. This is a qualitative assignment, not a quantitative determination.

Conclusion

LC-MS screening result: Tesamorelin-related peptide material detected, with a principal chromatographic feature near RT 5.433 min and a multiply charged ion pattern consistent with the expected mass region. Definitive intact-mass identity and quantitative purity confirmation would require a suitable higher-resolution/deconvoluted LC-MS method and, where applicable, orthogonal purity testing.

Analytical note

The observations are qualitative and intended for screening/characterization; they are not a quantitative assay or certificate of purity.

TEST REPORT

111l-0
JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #237184

Testing ordered > 22 SEP '26
Sample received > 06 OCT '26

Client SPEPS/group
Sample Tesamorelin 10mg
Manufacturer SPEPS/group
Batch

Sample description >

See picture or pictures attached.

Tests requested >

Endotoxin Analysis

Results >

Endotoxin	<1 EU/Vial.

Comments>

Analysis conducted > 09 OCT 2026

Signature>



TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #237186

Testing ordered > 22 SEP '26

Sample received > 06 OCT '26

Client SPEPS/group

Sample Tesamorelin 10mg

Manufacturer SPEPS/group

Batch

Sample description >

See picture or pictures attached.

Tests requested >

Heavy Metals Analysis

Results >

As	not detected.
Cd	not detected.
Pb	not detected.

Comments>

Hg: not detected.

Analysis conducted > 07 OCT 2026

Signature>

